Navigation Links
Spectral announces 2008 financial results

TORONTO, March 12 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced its operational highlights and financial results for the fiscal year ended December 31, 2008.

"In 2008, we accomplished several key objectives on our path to delivering an effective treatment for severe sepsis for the U.S. market," said Dr. Paul Walker, President and CEO of Spectral. "In September, we agreed to key terms with Toray Industries, Inc. (Toray) of Japan to obtain the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream, and which has been used on more than 70,000 patients to date, primarily in Europe and Japan. Together with our proprietary Endotoxin Activity Assay (EAA(TM)), used for measuring endotoxin levels in the blood, the combination has demonstrated a dramatic reduction in the mortality of patients with severe sepsis compared to standard of care in European trials. Spectral's current focus is to seek FDA clearance for the therapeutic product."

    Highlights from 2008:

    -   Agreed to key terms with Toray, in September 2008, to obtain the
        exclusive development and commercial rights in the U.S. for
        Toraymyxin(TM). The Company will now seek FDA clearance for this
        product. The final license and supply agreement with Toray was signed
        subsequent to the year end on March 6, 2009.

    -   Presented findings showing the clinical effectiveness of EAA(TM) to
        identify patients with elevated endotoxin levels and to guide
        endotoxin reducing strategies at a symposium entitled "Blood
        Purification in the Treatment of Sepsis," at the International Shock
        Congress in Cologne, Germany in June 2008.

    -   Entered into an exclusive distribution agreement in July 2008 with BB
        Medical, a leading distributor of medical technologies in Russia, for
        Spectral's EAA(TM). Under the terms of the agreement, BB Medical will
        market and sell EAA(TM) throughout the Russian Federation starting in

    -   Expanded collaboration agreement with Toray in May 2008, gaining
        access to Toray's distributors in new geographic territories
        including China, India, Russia and Canada for the sales and promotion
        of EAA(TM) in combination with Toraymyxin(TM) and as a stand-alone

    -   Selected by a major international pharmaceutical company in April
        2008 to use EAA(TM) to measure endotoxin levels during the enrolment
        of patients in a Phase III sub study, part of a multinational
        clinical trial evaluating the safety and effectiveness of a treatment
        for severe sepsis.

Financial Review

For the three-months ended December 31, 2008, Spectral reported sales of $861,000 compared to $675,000 for the corresponding period in 2007. For the year ended December 31, 2008, Spectral reported sales of $3,011,000 compared to $2,993,000 for the corresponding period in 2007. In 2008, sales of the Company's EAA(TM) product more than doubled to $660,000, compared to $296,000 in the prior year. The distribution agreements signed in Japan, Italy, and Germany late in 2007 were primarily accountable for this revenue growth. Spectral expects further sales improvement from these existing arrangements and new sales from distribution agreements in Russia and India in 2009. Reagent sales of $239,000 in 2008 increased by 22% over last year and are expected to remain consistent in the next fiscal year. Certain pre-established royalty plateaus were reached in 2007 by a licensee of the Company's Troponin I technology, with a resultant reduction in related revenues of $641,000. In future years, a portion of this impact should be offset as revenues from a new license agreement, signed in late 2007, are realized.

Selling, general and administrative expenses for the year ended December 31, 2008 were $3,264,000, compared to $3,167,000 for the corresponding period in 2007, and are expected to remain at these levels due to the continued maintenance of a low cost operating structure.

Research and development costs for the year ended December 31, 2008 amounted to $75,000, compared to $66,000 in 2007. The Company does not expect to incur any significant research and development expenses related to its current business in 2009.

For the three-months ended December 31, 2008, the Company reported a loss of $303,000 or ($0.01) per share compared to a loss of $698,000 or ($0.03) per share for the corresponding period in 2007. For the year ended December 31, 2008, the Company reported a loss of $1,666,000 or ($0.06) per share compared to a loss of $1,725,000 or ($0.07) per share for the corresponding period in 2007.

Cash and short term investments at December 31, 2008 totalled $3,608,000 compared with $4,204,000 at December 31, 2007. Management expects that the Company will maintain a minimum cash and short term investment balance of $3,000,000 throughout the 2009 fiscal year.

The total number of shares outstanding for the Company was 24,118,424 as at March 11, 2009.

Notice of Annual General Meeting

Spectral will hold its Annual General Meeting of Shareholders at 4:00PM on May 14, 2009 at the offices of Stikeman, Elliott LLP, Suite 5300, 199 Bay Street, Toronto, Ontario.

About Spectral Diagnostics

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    Spectral Diagnostics Inc.
    Balance Sheets
    As at December 31, 2008 and 2007


    (in thousands of dollars)

                                                              2008      2007
                                                                 $         $

    Current assets
    Cash                                                       297       638
    Short-term investments                                   4,000     4,289
    Accounts receivable                                        860       677
    Inventories                                                203       249
    Prepaid expenses                                            42        55

                                                             5,402     5,908

    Property, plant and equipment, net                         493       379

    Commercial instruments, net                                132       164

    Purchased technology and trademarks, net                 1,058     1,529

                                                             7,085     7,980


    Current liabilities
    Accounts payable and accrued liabilities                   540       379

    Deferred revenue                                           322       150

    Convertible notes payable                                2,172     2,008

                                                             3,034     2,537

    Shareholders' Equity

    Common shares                                            2,524     2,524

    Other equity                                             5,716     5,606

    Deficit                                                 (4,189)   (2,687)

                                                             4,051     5,443

                                                             7,085     7,980

    Spectral Diagnostics Inc.
    Statements of Operations, Comprehensive Loss and Deficit
    For the years ended December 31, 2008 and 2007


    (in thousands of dollars, except share and per share data)

                                                        2008            2007
                                                           $               $

    Sales                                              3,011           2,993

    Cost of sales                                        796             855

    Gross margin                                       2,215           2,138

    Operating expenses
    Selling, general and administrative                3,264           3,167
    Amortization                                         592             536
    Foreign exchange (gain) loss                        (117)            102
    Stock-based compensation                             110             117
    Research and product development,
     net of tax credits                                   32             (59)

                                                       3,881           3,863

    Loss before the following                         (1,666)         (1,725)

    Interest expense on convertible notes payable       (164)           (165)

    Other net interest income                            328             224

    Loss and comprehensive loss for the year          (1,502)         (1,666)

    Deficit - Beginning of year                       (2,687)         (1,021)

    Deficit - End of year                             (4,189)         (2,687)

    Basic and diluted loss per common share            (0.06)          (0.07)

    Weighted average number of common
     shares outstanding                           24,118,424      24,117,333

    Spectral Diagnostics Inc.
    Statements of Cash Flows
    For the years ended December 31, 2008 and 2007


    (in thousands of dollars)
                                                              2008      2007
                                                                 $         $
    Cash provided by (used in)

    Operating activities
    Loss and comprehensive loss for the year                (1,502)   (1,666)
    Items not affecting cash
      Amortization                                             592       536
      Amortization of commercial instruments
       included in cost of sales                                76        63
      Loss on disposal of property, plant and equipment          -        46
      Writeoff of purchased technology and trademarks            -        66
      Stock-based compensation expense                         110       117
      Interest on convertible note payable                     164       165
    Changes in non-cash working capital                         37       (59)

                                                              (523)     (732)

    Investing activities
    Purchase of property, plant and equipment                 (235)     (280)
    Purchase of technology and trademarks                        -       (44)
    Purchase of commercial instruments                         (44)     (173)
    Decrease in short-term investments                         289       768
    Deferred revenue                                           172       150

                                                               182       421

    Financing activities
    Issuance of common shares                                    -         4

    Decrease in cash during the year                          (341)     (307)

    Cash - Beginning of year                                   638       945

    Cash - End of year                                         297       638

SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
2. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
3. Spectral announces third quarter 2008 results
4. Spectral to bring anti-sepsis therapy to the U.S. market
5. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
8. Spectral and Toray expand collaboration to include new geographic territories
9. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
10. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
11. Spectral announces 2007 financial results
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):